Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer
A 1-month formulation of the gonadotrophin-releasing hormone agonist (GnRHa) triptorelin (Decapeptyl®) has been approved in the EU as an adjuvant treatment in combination with tamoxifen or an aromatase inhibitor (AI), of endocrine-responsive, early-stage breast cancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy. This indication reflects the results of the 5-year SOFT and TEXT studies, especially SOFT, in which ovarian function suppression (OFS; mainly achieved with triptorelin) added to tamoxifen provided a significant benefit in the overall study population of premenopausal patients only after adjusting for prognostic factors. It emerged that adding OFS to tamoxifen produced more pronounced benefits in terms of disease control and, furthermore, increased overall survival in the cohort of higher-risk patients who had previously received chemotherapy. Also, compared with tamoxifen alone, the combination of OFS plus exemestane produced more pronounced benefits in terms of disease control than OFS plus tamoxifen. OFS induces premature menopause; when combined with either tamoxifen or exemestane, it increased the endocrine symptom burden. Nonetheless, the two combinations had distinct tolerability profiles (e.g. vasomotor symptoms and thromboembolic events were more frequent with OFS plus tamoxifen, whereas musculoskeletal symptoms, decreased libido, osteoporosis and fractures were more frequent with OFS plus exemestane). Thus, the combinations of OFS (with triptorelin) plus either tamoxifen or an AI are valid options for the adjuvant treatment of endocrine-responsive, early-stage breast cancer in women at sufficiently high risk of relapse to warrant receiving chemotherapy and who remain premenopausal thereafter. Individualized weighing of the potential benefits and adverse effects of treatment is required.
During the peer review process, the manufacturer of triptorelin was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
James Frampton is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/F2E8F06077AD8C95.
- 1.Pritchard KI, Hayes DF, Vora SR. Patient education: early stage breast cancer treatment in premenopausal women (beyond the basics). http://www.uptodate.com. Accessed 29 June 2017.
- 12.National Cancer Institue. Hormone therapy for breast cancer fact sheet. https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet. Accessed 29 June 2017.
- 15.Burstein HJ. Adjuvant medical therapy for HER2-positive breast cancer (beyond the basics). http://www.uptodate.com. Accessed 29 June 2017.
- 21.Burstein HJ. Adjuvant chemotherapy for HER2-negative breast cancer. http://www.uptodate.com. Accessed 29 June 2017.
- 22.Ipsen Ltd. Decapeptyl SR 3 mg: UK summary of product characteristics. 2017. https://www.medicines.org.uk. Accessed 21 June 2017.
- 23.Ipsen Ltd. Decapeptyl SR 11.25 mg: UK summary of product characteristics. 2016. https://www.medicines.org.uk. Accessed 21 June 2017.
- 24.Ipsen Ltd. Decapeptyl SR 22.5 mg: UK summary of product characteristics. 2016. https://www.medicines.org.uk. Accessed 21 June 2017.
- 30.Bellet M, Gray KP, Francis PA, et al. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy. J Clin Oncol. 2016;34(14):1584–93.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.US National Institutes of Health. ClinicalTrials.gov identifier NCT00066690. 2016. https://clinicaltrials.gov. Accessed 2 June 2017.
- 34.US National Institutes of Health. ClinicalTrials.gov identifier NCT00066703. 2016. https://clinicaltrials.gov. Accessed 2 June 2017.
- 37.Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015;16(7):848–58.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Ribi K, Luo W, Bernhard J, et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016;34(14):1601–10.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Fleming G, Francis PA, Láng E, et al. Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the SOFT trial [abstract]. In: San Antonio Breast Cancer Symposium. 2017.Google Scholar
- 40.Pagani O, Regan MM, Fleming GF, et al. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials [abstract]. In: San Antonio Breast Cancer Symposium. 2017.Google Scholar
- 41.Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34(19):2221–31.CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Regan MM, Walley BA, Francis PA, et al. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol. 2017;28(9):2225-32.CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Francis P, Fleming G, Regan M, et al. Long-term follow-up of TEXT and SOFT trials of adjuvant endocrine therapies for premenopausal women with HR+ early breast cancer [abstract no. OT3-02-03]. Cancer Res. 2017;77(4 Suppl).Google Scholar